Andrea Mambrini ^UDM

Andrea Mambrini is the CTO & Co-Founder at Exogene, a venture-backed biotechnology company. Exogene specializes in enabling the discovery of T-cell-receptor (TCR)-based cell therapies to combat solid tumors and reverse immune aging. Their approach involves combining artificial intelligence (AI) with high-throughput TCR screening in the lab. Exogene is developing an AI platform to computationally screen entire patient-derived TCR repertoires and identify rare, effective TCRs for cell therapy applications. The company has secured investments from Selvedge Venture, R42 Group, KQ Labs, Entrepreneur First, and others.